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AlkalineAbstract Background: Thalassemia syndromes are heterogeneous groups of inherited anemias. Its
treatment depends on recurrent blood transfusion with a problem of iron overload, which leads to
multiple endocrinopathies including hypoparathyroid. The aim of the study is to estimate the level
of serum parathyroid hormone and its relation to bone mineral density in transfusion dependent
beta-thalassemia major children.
Subjects and methods: We measured serum calcium, phosphorus and parathyroid hormone in a
sample of pediatric patients with thalassemia, compared them with age and sex matched healthy
control. Measurement of bone mineral density by dual-energy X-ray absorptiometry was done in
2 sites: lumbar spine (L2–L4) in the anteroposterior position and left femur neck using Lunar Den-
sitometry in osteoporosis Unit Ain Shams University Hospital for thalassemia patients.
Results: Thalassemic patients had significantly higher alkaline phosphatase and lower bone min-
eral density.
Conclusion: Osteopenia in b-thalassemia major patients is multifactorial and is mainly predis-
posed by defective function of the parathyroid gland and excessive iron deposition.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Beta-thalassemia is an inherited anemia caused by unbalanced
globin chain synthesis with ineffective erythropoiesis and
peripheral hemolysis [1].
The aim of treatment in thalassemia is to prevent anemia
and bone marrow hyperplasia by regular blood transfusion
[2]. Suboptimal transfusion causes bone marrow expansionensity; a
2 M. El-Nashar et al.and decreases cortical and trabecular bone tissues and osteo-
porosis [3].
With advance in blood transfusion management, classical
thalassemic bone changes reduced markedly. However, well
transfused patients require adequate iron chelation therapy
such as desferrioxamine. The latter has direct toxic effect on
bone growth [4,5]. It also chelates zinc which is a co-factor
for alkaline phosphatase. Iron overload may result in end
organ damage, especially in endocrine glands as parathyroid
glands [6]. Parathyroid hormone plays a central role in cal-
cium–phosphate metabolism thus bone remodeling and turn
over.
The etiology of bone disease in beta thalassemia is multifac-
torial. Factors such as bone marrow expansion, increased iron
load, hormonal deficiency, desferrioxamine side effects and
calcium/vitamin D deficiencies all seem to have a serious
impact on the impaired bone metabolism in the disease [7].
With this background, we were stimulated to assess bone
mineral density in children with beta-thalassemia major and
to find its relation with serum parathyroid hormone level.-2
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Figure 1 Comparison of Z-score of patients with normal bone
mineral density versus patients with osteopenia.2. Methods
This case-control study was conducted on 60 cases with beta-
thalassemia major diagnosed by elevated Hb F and A2 in
hemoglobin electrophoresis, attending Hematology clinic,
Pediatric Hospital, Ain Shams University.
They were 38 males and 22 females with male: female ratio
of 1.7:1. Their age ranged between 5 and 15 years with a mean
age of 9.4 ± 3.2 years.
The controls were 30 age-and sex matched, non-anemic
healthy children from Pediatric Outpatient clinic of Ain Shams
University Pediatric Hospital.
All study procedures were approved by the Ethics Commit-
tee of the Ain Shams University. All subjects were informed
orally about the procedures and the aim of the study and gave
written consent to participate. The consent of participation in
the study was signed by the parents or legal guardians of the
studied subjects. The work has been carried out in accordance
with the World Medical Association (declaration of Helsinki)
for experiments in humans.
All patients were subjected to the following:
1. Detailed history taking laying stress on patient age, disease
duration, frequency of blood transfusion, history of bone
pain or fracture, type and frequency of chelation therapy.
2. Thorough clinical examination with special emphasis on
weight, height, size of liver and spleen, presence of spleenec-
tomy scar, pallor, skeletal deformity bone fracture and
signs of haemosiderosis.
3. Quantitative measurement of serum calcium and phospho-
rous, alkaline phosphatase and parathyroid hormone
(PTH) for whole study population i.e. patients and controls
in order to detect variation in their levels in comparison
with normal population even when levels are within normal
ranges:
(a) Serum calcium and phosphorous with synchron CX-
7 auto-analyzer (Bechman Instruments
Incorporation).
(b) Alkaline phosphatase by kinetic photometric method
(Diagnostic Systems International Kit).Please cite this article in press as: El-Nashar M et al., Parathyroid hormone in pediat
case control study, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejm(c) Parathyroid hormone (PTH) with Immulite Analyzer
using chemiluminescent immunometric assay.
4. Measurement of bone mineral density for thalassemia
patients by dual-energy X-ray absorptiometry in 2 sites:
lumbar spine (L2–L4) in the anteroposterior position and
left femur neck using Lunar Densitometry.
2.1. Statistical analysis
Data were statistically analyzed using SPSS statistical package
version 10 (Echosoft Corp, USA, 2006).
3. Results
Thalassemia patients enrolled in the study were all transfusion
dependent, receiving approximately 15 ml of packed red blood
cells per kilogram body weight every 2–3 weeks. Patients were
on chelation therapy with desferrioxamine 4 times per week in
the form of overnight subcutaneous infusion over 8 h, dose
40 mg/kg body weight.
Mean age of patients was 9.37 ± 3.17 y, weight 30.47
± 9.26 kg, and height 124.5 ± 17.5 cm and mean hemoglobin
level was 8 ± 1.41 gm/dl. Calcium blood level was 8.8
± 1.35 mg/dl for patients and 10.1 ± 0.63 mg/dl for controls.
Phosphorous level was 4.24 ± 0.96 mg/dl for patients and
2.69 ± 0.67 mg/dl for controls and alkaline phosphatase value
was 234 ± 62 IU/L for patients and 199 ± 76.9 IU/L for
controls.
Parathyroid hormone was higher in patients than in con-
trols, 75.9 ± 76.28 versus 46 ± 15.55 with no statistical differ-
ence (P-value >0.05).
Among thalassemia patients 31 had normal bone mineral
density with z-score 0.55 ± 0.003 and 29 patients had
decreased bone mineral density with z-score 1.96 ± 0.54
(see Fig. 1 and Table 1).
Patients with osteopenia are predominantly males (38
patients-63.3%), and 29 females (36.7%). Among them 21
patients (72.4%) gave a history of bone ache and 9 (31%)
had a history of fracture.
Comparing both groups, thalassemia patients and the
healthy controls concerning calcium, phosphorous, alkaline
phosphatase and parathyroid hormone showed that calcium,ric patients with b-thalassemia major and its relation to bone mineral density; a
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Parameter Paents with 
normal 
BMD (n=31) 
Paents with 
decreased 
BMD (n=29) 
P 
Calcium
(mg/dl) 
Phosphorous 
(mg/dl) 
Alkaline 
phosphatase 
(IU/L) 
Parathyroid 
hormone 
(pg/ml) 
Ferrin 
(ng/ml) 
9.42±0.98
3.97±0.89 
230±67.2 
110±88.2 
591.6±294 
8.18±1.4
4.51±0.958 
238±56.86 
39.5±35.56 
1603±717.9 
<0.001 
<0.05 
>0.05 
<0.001 
<0.001 
Figure 2 Comparison of bone markers between patients with
normal bone mineral density versus patients with osteopenia.
Table 1 Results of bone mineral density of beta-thalassemia
patients group.
Parameter Patients with
normal
BMD (n= 31)
Patients with
decreased
BMD (n= 29)
P
Z score 0.55 ± 0.003 1.96 ± 0.54 <0.001
Parathyroid hormone and bone mineral density in beta thalassemia major patients 3parathyroid hormone were higher in thalassemia patients with
normal bone mineral density while phosphorous, alkaline
phosphatase and serum ferritin were higher in thalassemia
patients with osteopenia (see Fig. 2).
4. Discussion
Historically, beta-thalassemia major has been associated with
marked osseous changes, originally described by Coley et al.
The life expectancy of patients with b-thalassemia has greatly
improved with increase in serious complications including
osteopenia and osteoporosis [8]. With advances in blood trans-
fusion, classical thalassemia bone changes showed a mild
reduction, however suboptimal blood transfusion together
with inadequate iron chelation therapy lead to chronic anemia,
hypoxia and iron overload [4]. As a consequence, impaired
growth and delayed puberty are common findings; therefore,
skeletal changes in these patients are prominent despite a lesser
severity of disease [7].
The current study revealed a marked reduction in calcium
level and increase in phosphorus and alkaline phosphatase
levels in thalassemia patients compared to the control group.
Saboor et al. reported same findings [5]. Lasco et al., also
reported the same and mentioned that this calcium phosphorus
unbalanced ratio resulted from parathyroid affection as a part
of multiple endocrinopathies resulting from iron overload. In
contrast [4], Mahackolertwattana et al., reported that calcium
and phosphorous were nearly the same in both groups’ tha-
lassemia patients and controls [7].
In our research, we studied the level of parathyroid hor-
mone in both groups and found a non significant difference
with a higher level in patients group. Also, Napoli et al.Please cite this article in press as: El-Nashar M et al., Parathyroid hormone in pediat
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patients despite the presence of hypocalcemia and hyperphos-
phatemia in most of them. This could be attributed to the
wideness in parathyroid hormone level range or the young
age of patients [8].
Abdel-Hafez and colleagues conducted a prospective
research evaluating endocrinal status in b-thalassemia children
and they found a significant decrease in parathyroid hormone
levels in the thalassemia group compared to the control group.
They owed their findings mainly to iron deposition in the
parathyroid gland due to frequent blood transfusion and inad-
equate chelation therapy [9].
Regarding the blood picture evaluation, hemoglobin level
was significantly lower in thalassemia patients compared to
controls, total leucocyte count is found to be higher in tha-
lassemia patients compared to controls, and this is mostly
due to increased susceptibility to infection present in the for-
mer group [6].
Platelets count is markedly increased in the thalassemia
group, mostly as a part of increased abnormal activity of bone
marrow precursors in response to tissue hypoxia [10].
The present study reported unbalanced calcium, phospho-
rous ratio in thalassemia patients having osteoporosis which
could be a predisposing factor for bone affection. This in
agreement with Vaskaridou et al. who stated also that longer
duration of disease, is associated with more affection to bone
density [11].
Serum ferritin was higher in osteopenic patients among the
thalassemia group. Jensen et al. stated that bone mineral den-
sity is affected in thalassemia patients with normal ferritin
levels, but Oudit et al. found high serum ferritin in osteopenic
patients [12]. This is could be explained by inhibition of
osteoblastic activity by iron, affection of anabolic factor as
IGF as a part of endocrinopathies or inhibition of DNA syn-
thesis by desferrioxamine which is an infrequently used iron
chelator.
Regarding the parathyroid hormone level, our study found
that the level of the hormone is markedly decreased in the
osteopenic group than in the normal bone mineral density
group. Skordis et al. found that the difference in the hormone
level between the two groups was insignificant [13].
Aim of thalassemia treatment in pre-pubertal children has
been changed from not only treatment of anemia and skeletal
changes to treatment of bone morbidities but also osteoporosis
which became an important problem [14]. The decrease in bone
density starts early in childhood and becomes progressive with
age. Even in some well chelated population a problem of low
bone mineral density still exists, especially those treated with
desferioxamine [15]. However, no significant relationship
between its use andbonemineral densitywas found in our study.
In conclusion, our study showed that osteopenia which is a
common complication in b-thalassemia major patients is mul-
tifactorial and is mainly predisposed by defective function of
parathyroid gland and excessive iron deposition in various
body organs.
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